Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2016

  • ID: 3946385
  • Drug Pipelines
  • 62 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Agilvax, Inc.
  • Biogenomics Limited
  • BioMAS Ltd.
  • Cutanea Life Sciences Inc
  • LEO Pharma A/S
  • Novan, Inc.
  • MORE
Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Genital Warts - Pipeline Review, H2 2016, provides an overview of the Genital Warts (Infectious Disease) pipeline landscape.

Genital warts (condyloma acuminata) are one of the most common types of sexually transmitted infections. Genital warts are caused by the human papillomavirus (HPV). Symptoms include small, flesh-colored or gray swellings in genital area, itching or discomfort in genital area, pain during intercourse and frequent urination. Treatment includes antiviral drugs and surgery.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Genital Warts - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Genital Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Genital Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Warts (Condylomata Acuminata) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 8, 1, 4 and 2 respectively for Genital Warts.

Genital Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Warts (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Genital Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Genital Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Genital Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Genital Warts (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Genital Warts (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Genital Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Agilvax, Inc.
  • Biogenomics Limited
  • BioMAS Ltd.
  • Cutanea Life Sciences Inc
  • LEO Pharma A/S
  • Novan, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Genital Warts (Condylomata Acuminata) Overview

Therapeutics Development

Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview

Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies

Genital Warts (Condylomata Acuminata) - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Genital Warts (Condylomata Acuminata) - Products under Development by Companies

Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development

Agilvax, Inc.

Aviragen Therapeutics, Inc.

Biogenomics Limited

BioMAS Ltd.

Cutanea Life Sciences Inc

Foamix Pharmaceuticals Ltd.

G&E Herbal Biotechnology Co., Ltd.

Laboratories Ojer Pharma S.L.

LEO Pharma A/S

Novan, Inc.

Novartis AG

Tamir Biotechnology, Inc.

Zydus Cadila Healthcare Limited

Genital Warts (Condylomata Acuminata) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AX-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BTA-074 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-0602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imiquimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imiquimod SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ingenol mebutate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon alfa-2b - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LFX-453 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omiganan pentahydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranpirnase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRT-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Genital Warts (Condylomata Acuminata) - Dormant Projects

Genital Warts (Condylomata Acuminata) - Discontinued Products

Genital Warts (Condylomata Acuminata) - Product Development Milestones

Featured News & Press Releases

May 10, 2016: Novan to Present Anti-viral Data for Nitric Oxide Product Candidate SB206

May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Genital Warts (Condylomata Acuminata), H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Agilvax, Inc., H2 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Aviragen Therapeutics, Inc., H2 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Biogenomics Limited, H2 2016

Genital Warts (Condylomata Acuminata) - Pipeline by BioMAS Ltd., H2 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Cutanea Life Sciences Inc, H2 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016

Genital Warts (Condylomata Acuminata) - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Laboratories Ojer Pharma S.L., H2 2016

Genital Warts (Condylomata Acuminata) - Pipeline by LEO Pharma A/S, H2 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Novan, Inc., H2 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Novartis AG, H2 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Tamir Biotechnology, Inc., H2 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Zydus Cadila Healthcare Limited, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Genital Warts (Condylomata Acuminata) - Dormant Projects, H2 2016

Genital Warts (Condylomata Acuminata) - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Genital Warts (Condylomata Acuminata), H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Agilvax, Inc.
Aviragen Therapeutics, Inc.
Biogenomics Limited
BioMAS Ltd.
Cutanea Life Sciences Inc
Foamix Pharmaceuticals Ltd.
G&E Herbal Biotechnology Co., Ltd.
Laboratories Ojer Pharma S.L.
LEO Pharma A/S
Novan, Inc.
Novartis AG
Tamir Biotechnology, Inc.
Zydus Cadila Healthcare Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll